Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caraco, MedImmune Settle Ethyol ANDA Patent Litigation
Caraco has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the US District Court for the District of Maryland. The case was
Caraco has executed a settlement agreement with MedImmune, stipulating the dismissal of the lawsuits filed in the US District Court for the District of Maryland. The case was
Amgen has reported positive top-line results from a pivotal phase 3 head-to-head trial evaluating denosumab. The study of denosumab, administered subcutaneously versus Zometa administered as an intravenous (IV)
Law firm, Glancy Binkow & Goldberg has filed a lawsuit in the US District Court of Massachusetts, seeking a class action status on behalf of a class consisting
XenoPort has planned to file a new drug application (NDA) in Japan for XP13512 (ASP8825), as a potential treatment for moderate-to-severe primary restless legs syndrome (RLS), in the
In the second quarter of 2009, ZymoGenetics’ net loss improved to $27 million, or $0.39 per share, from $37.4 million, or $0.54 per share, for the second quarter
MAP Pharmaceuticals has reported net loss for the quarter ended June 30, 2009 of $5 million, as compared to $16.5 million during the same period in 2008. The
Æterna Zentaris reported that Keryx has reached an agreement with FDA regarding a Special Protocol Assessment (SPA) on the design of a phase 3 trial for PI3K/Akt pathway
SuperGen has reported preliminary results from phase Ib data of MP-470, tyrosine kinase and RAD51 suppressor. The results demonstrated an overall clinical benefit rate of 54%, when the
Sinovac has reported that the clinical trial of its A/H1N1 influenza vaccine is proceeding well. All of the volunteers have received their first shot of the vaccine and,
Micromet has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103), for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody